We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Circadian rhythms
- RevERB structure and function
- RevERB ligands
- Physiological roles of revERBs
- Therapeutic potential
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2025, August 31). Rev-ERB (NR1D): biological role and ligands [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved September 3, 2025, from https://doi.org/10.69645/EPOT3417.Export Citation (RIS)
Publication History
- Published on August 31, 2025
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Other Talks in the Series: Nuclear Receptors as Common Therapeutic Targets
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome, everyone, to Chapter 13
of this short talk series
on nuclear receptors as
therapeutic targets.
0:09
This chapter deals with
the NR1D receptors
revERB-alpha and revERB-beta,
their biological roles
and their ligands.
The receptor acronym revERBA
originates from the finding
that revERB-alpha is
encoded on the opposite
or reverse strand
of the ERBA gene,
which is an old acronym
for the thyroid hormone
receptor alpha.
There is no similar relation
like this for revERB-beta.
0:39
NR1D receptors play
an important role
in the regulation of
circadian rhythms.
The circadian rhythm is a
cyclic biological process
running approximately 24 hours.
With the circadian rhythm,
for example, alertness and
tiredness, coordination,
body temperature, blood
pressure, hormone levels,
and many other
physiological processes
oscillate over the day.
1:03
Circadian rhythm is
mainly regulated by
the oscillating expression of
transcriptional activators
and repressors,
which form the so-called
circadian clock.
These transcription
factors mutually regulate
their expression levels
and feedback loops.
Additionally, post-translational
modifications,
like phosphorylation,
contribute to their regulation.
The main components
of this system are
the nuclear receptors of
the NR1D family, revERB,
and the NR1F family, ROR,
which we will deal with
in the next chapter.
The transcription
factors are CLOCK,
Circadian Locomotor
Output Cycles Kaput,
and BMAL1,
standing for Basic Helix-Loop-Helix
ARNT-Like protein 1,
which typically also
act as heterodimer,
and the period circadian
protein homologs,
abbreviated as PER,
which are transcriptional
repressors,
as well as the circadian
cryptochromes,
abbreviated as CRY,
which are light-sensitive
flavoproteins
that can also repress
the CLOCK-BMAL1 complex.